AngioChem
Clinical-stage biotechnology company developing engineered brain-targeting peptides and peptide-conjugation chemistries to transport small molecules, antibodies and enzymes across the blood–brain barrier. Pipeline areas include CNS oncology, analgesia and enzyme-replacement strategies for lysosomal storage diseases; programs have progressed through preclinical studies and multiple clinical trials.
Industries
Nr. of Employees
small (1-50)
Patents
Pharmaceutical compositions of paclitaxel, paclitaxel analogs or paclitaxel conjugates and related methods of preparation and use
US-8710013-B2
View Details
Pharmaceutical compositions of paclitaxel, paclitaxel analogs or paclitaxel conjugates and related methods of preparation and use
US-8710013-B2
View DetailsProducts
Clinical-stage brain-penetrant peptide–paclitaxel conjugate
Peptide–paclitaxel conjugate designed to penetrate the blood–brain barrier via receptor-mediated transport and enter tumor cells; evaluated in early- and late-stage clinical trials for primary and metastatic brain tumors.
Preclinical peptide–antibody conjugate for CNS targeting
Peptide-conjugated antibody approach engineered to enable systemic antibodies to penetrate brain parenchyma and target intracranial tumors in preclinical models.
Preclinical peptide–neurotensin analgesic conjugate
Peptide–neurotensin conjugate designed to enable CNS delivery of neurotensin for analgesic applications; demonstrated antinociceptive activity in preclinical pain models.
Peptide–enzyme conjugates for CNS enzyme-replacement therapy
Conjugation of brain-targeting peptides to lysosomal enzymes to reduce peripheral clearance, increase brain penetration and enable lysosomal uptake for treatment of neurological manifestations of lysosomal storage diseases.
Clinical-stage brain-penetrant peptide–paclitaxel conjugate
Peptide–paclitaxel conjugate designed to penetrate the blood–brain barrier via receptor-mediated transport and enter tumor cells; evaluated in early- and late-stage clinical trials for primary and metastatic brain tumors.
Preclinical peptide–antibody conjugate for CNS targeting
Peptide-conjugated antibody approach engineered to enable systemic antibodies to penetrate brain parenchyma and target intracranial tumors in preclinical models.
Preclinical peptide–neurotensin analgesic conjugate
Peptide–neurotensin conjugate designed to enable CNS delivery of neurotensin for analgesic applications; demonstrated antinociceptive activity in preclinical pain models.
Peptide–enzyme conjugates for CNS enzyme-replacement therapy
Conjugation of brain-targeting peptides to lysosomal enzymes to reduce peripheral clearance, increase brain penetration and enable lysosomal uptake for treatment of neurological manifestations of lysosomal storage diseases.
Services
Partnering for platform- and product-stage collaborations including licensing and co-development of brain-targeting therapeutics.
Partnering for platform- and product-stage collaborations including licensing and co-development of brain-targeting therapeutics.
Expertise Areas
- Blood–brain barrier drug delivery
- Clinical trial management for CNS indications
- Peptide design and conjugation chemistry
- Biologic and small-molecule conjugates for CNS delivery
Key Technologies
- Receptor-mediated transcytosis (LRP-1)
- Engineered brain-targeting peptides
- Peptide–drug conjugation chemistry
- Peptide–antibody conjugation
News & Updates
Regulatory orphan drug designation granted for a lead brain-penetrant oncology program.
Announcement of a Special Protocol Assessment interaction for a clinical program.
Granted a $4 million loan from the Quebec Government (BioMed Propulsion program) to support conduct of a Phase III clinical trial.
Received an innovation award recognizing progress toward developing brain-penetrant treatments for brain tumors.
Listed on an industry compilation recognizing innovative biotechnology companies.
Regulatory orphan drug designation granted for a lead brain-penetrant oncology program.
Announcement of a Special Protocol Assessment interaction for a clinical program.
Granted a $4 million loan from the Quebec Government (BioMed Propulsion program) to support conduct of a Phase III clinical trial.
Received an innovation award recognizing progress toward developing brain-penetrant treatments for brain tumors.
Listed on an industry compilation recognizing innovative biotechnology companies.